Fog horn leg horn video7/30/2023 The Company plans to present the full results at a future scientific meeting.įoghorn plans to dose the first patient in a Phase 1 study of FHD-286 in combination with decitabine or cytarabine in relapsed and/or refractory AML patients in the third quarter of 2023.įHD-286 is a highly potent, selective, allosteric and orally available, small-molecule, enzymatic inhibitor of BRG1 (SMARCA4) and BRM (SMARCA2), two highly similar proteins that are the ATPases, or the catalytic engines of the BAF complex, one of the key regulators within the chromatin regulatory system. The trial evaluated 73 metastatic uveal melanoma patients who had been treated with a median of two prior therapies across nine different cohorts. We plan to initiate dosing the FHD-286 combination study in relapsed/refractory AML during the third quarter of 2023 and continue to invest in our promising pre-clinical programs such as Selective-BRM, CBP, EP300, and ARID1B.”įHD-286 Phase 1 Dose Escalation Study Data in Metastatic Uveal Melanoma In the study, nine patients had stable disease and one patient had a durable partial response,” said Adrian Gottschalk, President and Chief Executive Officer of Foghorn. “However, Foghorn does not plan to pursue this indication on its own. “The clinical data further support the safety and tolerability of FHD-286 and build on the previously disclosed AML/MDS data. At this time, the company does not plan to advance FHD-286 in uveal melanoma. These data reinforce the safety and tolerability profile of FHD-286. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious disease by correcting abnormal gene expression, today announced data from the Phase 1 dose escalation safety study of FHD-286 in metastatic uveal melanoma (mUM). Foghorn anticipates initiating a FHD-286 combination study in relapsed/refractory AML during the third quarter of 2023ĬAMBRIDGE, Mass., J(GLOBE NEWSWIRE) - Foghorn ® Therapeutics Inc. Foghorn does not plan to advance FHD-286 in uveal melanoma Clinical activity observed in late-line metastatic uveal melanoma includes nine patients with stable disease and one patient with a confirmed partial response selective, allosteric, oral, small molecule inhibitor of BRG1/BRM DVD, English and Mandarin, Concealed Subtitles in Regular and Simplified Characters, Approx 50 Min.- Clinical data support safety and tolerability profile of FHD-286, a highly potent, Bilingual in Mandarin and English, with concealed subtitles in simplified and traditional Chinese characters. Claude then taunts Marc with images of kitten abuse, the bulldog finding a way to get at him from the porch by tossing a small but effective lasso and the fight is on! This hilarious DVD is such a classic, it can easily be a collector's item! This compilation DVD contains the following titles: Quacker Tracker Double or Mutton Feline Frame-Up 8 Ball Bunny A Fractured Leghorn Scaredy Cat Come Back to Me. Claude is a rival for the master's attention (and the soft pillows), so he frames the big lug, making it look like Marc has consumed the kitten. A great treat for fans of Foghorn Leghorn, Daffy Duck and all of their farm friends! Marc Antony again risks embarrassment to his bulldog masculinity to protect his dear, helpless baby kitten Pussyfoot from his genuinely evil adversary, Claude Cat.
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |